Agnosia for Pain
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Inhibiting the induced brain CYP2D reversed the change in oxycodone levels (1.2-fold; P > 0.1) and analgesia (1.1-fold; P > 0.3).
|
29266563 |
2019 |
Lung Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues.
|
9205060 |
1997 |
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to evaluate the possible pharmacokinetic changes in NAFLD as a result of reduced metabolic activity of CYP2D.
|
30786957 |
2019 |
Mental Depression
|
0.210 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
Mental Depression
|
0.210 |
Biomarker
|
disease |
RGD |
Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression.
|
20595028 |
2010 |
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We have refined the location of one possible tumour suppressor gene to the region between the microsatellite markers D22S299 and CYP2D.
|
10956388 |
2000 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q.
|
8631002 |
1996 |
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
Catalepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective inhibition and induction of brain, but not liver, CYP2D decreased and increased catalepsy after acute haloperidol, respectively.
|
28454738 |
2017 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
Gilbert Disease (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gilbert's syndrome, a genetic deficiency in bilirubin UDP-glucuronosyltransferase (UGT1A1), may dispose to increased toxicity of propafenone in poor metabolizers (PMs) of cytochrome P4502D6 because glucuronidation of propafenone is the major metabolic pathway for drug elimination in PMs.
|
10850406 |
2000 |
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
Amelogenesis Imperfecta, Type IB
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders.
|
10534269 |
1999 |
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |